TRANSCODE THERAPEUTICS, INC.

BOSTON, MA

OncologyGrant-onlyListed · RNAZ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

NIH R44 · $1.0M · Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer

Jun 2025Grant renewalJun 19, 2025Source filing (opens the source filing in a new tab)

Momentum

20no change

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R44 · $989k · non-dilutive
Sep 4, 2024
TRANSCODE THERAPEUTICS, INC. · PI MEDAROVA, ZDRAVKA O · NCI · award ends Aug 31, 2026 · Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer
NIH RePORTER · NIH RePORTER 11182730 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

new_entity links the grant record at 0.31{"reasons":["same city","same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R44 · $1.0M · Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer
Jun 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R44 · $989k · non-dilutive